Global Ganja Report

President Donlad Trump on April 18 signed an executive order calling on the DEA and FDA to open legal pathways for research into the therapeutic benefits of certain Schedule I psychedelic drugs—prominently including ibogaine, with an emphasis on its potential to treat PTSD in military veterans. The order instructs the FDA to collaborate with the Department of Veterans Affairs and the private sector "to increase clinical trial participation and evidence generation surrounding experimental psychedelic therapies." 

President Donald Trump signed an executive order Dec. 18 to accelerate the reclassification of marijuana, a move that would ease decades-old restrictions that have classified the drug alongside heroin as having no accepted medical value.

The US Controlled Substances Act ranks drugs along a five-tier spectrum based on their potential for abuse and recognized medical value. Schedule I drugs are those with a high likelihood of abuse, no accepted medical use, and considerable health risks even when administered under medical supervision. Since 1970, marijuana has been listed alongside heroin as a Schedule I drug. Schedule V drugs are those with accepted medical uses and a relatively low likelihood of abuse.

It was federal subsidies for healthcare that were center-stage in the government shutdown and the Capitol Hill deal that finally ended it. But the fight over the heretofore ambiguous legal status of hemp-derived THC was also at issue in the end—and this could represent a serious blow to America’s farmers.

As their name implies, World Breeders is a cannabis seed company with a planetary consciousness. Co-director Gorka Cid Luaces says he is proud of the founders' trajectory from the "underground side" to an enterprise with operations on three continents, and an ambition to "export THC seed worldwide."

Texas Gov. Greg Abbott on June 11 signed a bill creating a consortium of universities, hospitals and pharmaceutical firms to conduct clinical trials on ibogaine, in hopes of receiving US Food & Drug Administration approval. The press release on the signing hails ibogaine as an "emerging treatment for neurological and mental health conditions." Lawmakers approved $50 million to support the effort, making Texas the global leader in psychedelic research investment. (Texas Tribune)

In a last-minute move before the measure was to automatically become law, Gov. Greg Abbott on June 23 vetoed Senate Bill 3, which sought to ban the sale of all THC-laden products in Texas, whether Delta-8 and Delta-9. The bill would have also placed greater restrictions on CBD products, such as banning their sale to those under 21. Abbott has called for a special legislative session to revisit the question, which has pitted the hemp industry against the GOP establishment. Abbott's own Lt. Gov. Dan Patrick was a key advocate of the "THC ban." Patrick bashed Abbott over the veto, saying he "wants to legalize recreational marijuana."

In the big — and, in nearly half of US states now, successful — drive to legalize cannabis, two major arguments have been brought to bear. First, that public oversight of a legal industry will assure transparency and standards for quality. And secondly, that a taxed industry will be a boon to state and local economies.

But now a disturbing new study from an industry advocacy group in California indicates that the legal cannabis sector faces a challenge in the proliferation of ostensibly legal but in fact unregulated psychoactive “hemp” products.

Rights for medicinal cannabis users in the workplace have not kept pace with the law in states that have embraced medical and even “recreational” use. Now a case in Vermont may push state and federal authorities alike to close the loopholes that allow workers to be dismissed—and denied unemployment insurance—for using state-legal medicine.